search
Back to results

Humidified Forest Oils for Immune System Recovery in Stage I-III Breast or Prostate Cancer

Primary Purpose

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8

Status
Enrolling by invitation
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Aromatherapy with Essential Oils
Sponsored by
OHSU Knight Cancer Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Anatomic Stage I Breast Cancer AJCC v8

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age >= 18 years. Both men and women and members of all races and ethnic groups will be included
  • Participants must have histologically or cytologically confirmed hormone receptor positive (HR+) HER2 negative (-) breast cancer or prostate cancer (hormone therapy excepted) who are in Stage I-III with no evidence of metastasis using the Cancer Therapy Evaluation Program (CTEP) Simplified Disease Classification
  • Criteria for solid tumors: Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam
  • Participants must have no history of autoimmune disease
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • If they have asthma. Rationale: forest oils may be a possible trigger for asthma)
  • If they have a known allergy to citrus peel or pine forests. Rationale: forest oils may cause contact dermatitis and coughing
  • If they are unable to detect common odors from commercial fragrances. Rationale, forest oils are humidified as an aroma to be inhaled in the simulate the forest greenspace immersion (SFIT)
  • If they have known metastases should be excluded from this clinical study. Rationale, because of their poor prognosis rather than being in early stages of cancer
  • Febrile illness/infection within previous two weeks. Rationale, immune biomarkers will reflect previous febrile illness
  • Current tobacco or tobacco use within 1 hour of start of SFIT. Rationale: forest oils may cause contact dermatitis and coughing
  • Prior autoimmune disease, are on immune-modulating therapies (endocrine therapy allowed). Rationale, because of their poor prognosis rather than being in early stages of cancer
  • Had surgery or invasive procedure in the past two months. Rationale, because of their poor prognosis rather than being in early stages of cancer
  • Inability to complete study requisites

Sites / Locations

  • OHSU Knight Cancer Institute

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Supportive care (SFIT, biospecimen, interview)

Arm Description

Patients participate in SFIT, using humidified wood and fragrance oils, over 1 hour. Patients also undergo blood sample collection at baseline and on day 3 or 4 and participate in interviews at baseline and post-treatment.

Outcomes

Primary Outcome Measures

Humidified phytoncides to simulate the forest greenspace immersion (SFIT)
Feasibility analysis will include qualitative interview data blinded by participant, CRC/research assistant and principal investigator. Qualitative interview questions include ease of use/deployment of humidified forest oils by the CRC/research assistant and PI, the ability of the participants to tolerate SFIT. The responses will be coded, themed and summarized will be used to determine the feasibility of intervention deployment and creation of a standardized procedure for future research. To determine dose drop off between the start of SFIT and the end of SFIT of the humidified phytoncides a t-test with an alpha level of 0.05 will be used.

Secondary Outcome Measures

Collecting and analyzing immune system measures while deploying the simulated forest immersion therapy with forest oils
Will measure natural killer (NK) cell number and activity, and perforin and granulysin. NK cell number (NK CD3-/CD56+/) and activity (NK CD3-/CD56+/CD69+) will be tested with Flow Cytology. Perforin and granulysin will be tested by ELISA. Will use a t-test to determine the differences between these 4 variables collected at baseline and a Day 3-4. An alpha level of 0.05 will be set. Alternate analysis, the change NK cell number and activity will be determined from the mean of the standard range.

Full Information

First Posted
August 6, 2021
Last Updated
June 7, 2023
Sponsor
OHSU Knight Cancer Institute
Collaborators
Oregon Health and Science University
search

1. Study Identification

Unique Protocol Identification Number
NCT05012813
Brief Title
Humidified Forest Oils for Immune System Recovery in Stage I-III Breast or Prostate Cancer
Official Title
Feasibility of Substitution of Volatile Organic Compound Humidification to Simulate the Forest Experience Effects on Immune System Recovery
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
July 19, 2022 (Actual)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
OHSU Knight Cancer Institute
Collaborators
Oregon Health and Science University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This clinical trial studies the feasibility of simulating forest therapy using humidified wood or fragrant oils, in improving immune cells, like natural killer cells, number and activity, and their downstream proteins, perforin and granulysin in patients with stage I-III breast or prostate cancer who completed chemo- and/or radiation therapy. The knowledge gained from this study may help cancer patients who have compromised immune systems and who also cannot participate in outdoor activities like exercise or forest walks.
Detailed Description
PRIMARY OBJECTIVE: I. Determine the feasibility of using humidified phytoncides to simulate the forest greenspace immersion (simulated forest immersion therapy [SFIT]) in cancer patients with solid tumor who have completed surgery, chemo- and radiation therapy as an alternate method of access to the natural forest greenspace. SECONDARY OBJECTIVE: I. Determine the feasibility of collecting and analyzing immune system measures while deploying the simulated forest immersion therapy with forest oils (SFIT), as well as measuring natural killer (NK) cell number and activity, and perforin and granulysin. OUTLINE: Patients participate in SFIT, using humidified wood and fragrance oils, over 1 hour. Patients also undergo blood sample collection at baseline and on day 3 or 4 and participate in interviews at baseline and post-treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Malignant Solid Neoplasm, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
25 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Supportive care (SFIT, biospecimen, interview)
Arm Type
Experimental
Arm Description
Patients participate in SFIT, using humidified wood and fragrance oils, over 1 hour. Patients also undergo blood sample collection at baseline and on day 3 or 4 and participate in interviews at baseline and post-treatment.
Intervention Type
Other
Intervention Name(s)
Aromatherapy with Essential Oils
Other Intervention Name(s)
Therapeutic Interventions, Therapeutic Method, Therapeutic Procedure, Therapeutic Technique, Therapy
Intervention Description
Participate in SFIT this is one intervention with aroma therapy with essential Forest oils
Primary Outcome Measure Information:
Title
Humidified phytoncides to simulate the forest greenspace immersion (SFIT)
Description
Feasibility analysis will include qualitative interview data blinded by participant, CRC/research assistant and principal investigator. Qualitative interview questions include ease of use/deployment of humidified forest oils by the CRC/research assistant and PI, the ability of the participants to tolerate SFIT. The responses will be coded, themed and summarized will be used to determine the feasibility of intervention deployment and creation of a standardized procedure for future research. To determine dose drop off between the start of SFIT and the end of SFIT of the humidified phytoncides a t-test with an alpha level of 0.05 will be used.
Time Frame
Baseline/Day 1
Secondary Outcome Measure Information:
Title
Collecting and analyzing immune system measures while deploying the simulated forest immersion therapy with forest oils
Description
Will measure natural killer (NK) cell number and activity, and perforin and granulysin. NK cell number (NK CD3-/CD56+/) and activity (NK CD3-/CD56+/CD69+) will be tested with Flow Cytology. Perforin and granulysin will be tested by ELISA. Will use a t-test to determine the differences between these 4 variables collected at baseline and a Day 3-4. An alpha level of 0.05 will be set. Alternate analysis, the change NK cell number and activity will be determined from the mean of the standard range.
Time Frame
Baseline and at day 3 or 4

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age >= 18 years. Both men and women and members of all races and ethnic groups will be included Participants must have histologically or cytologically confirmed hormone receptor positive (HR+) HER2 negative (-) breast cancer or prostate cancer (hormone therapy excepted) who are in Stage I-III with or without evidence of metastasis using the Cancer Therapy Evaluation Program (CTEP) Simplified Disease Classification Participants must be within 12 months of their first diagnosis of breast or prostate cancer Criteria for solid tumors: Participants must have measurable disease, per MD and data in medical record Participants must have no history of autoimmune disease Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: If they have asthma. Rationale: forest oils may be a possible trigger for asthma) If they have a known allergy to citrus peel or pine forests. Rationale: forest oils may cause contact dermatitis and coughing If they are unable to detect common odors from commercial fragrances. Rationale, forest oils are humidified as an aroma to be inhaled in the simulate the forest greenspace immersion (SFIT) First diagnosis of breast or prostate cancer is longer than 12 months ago. Rationale, NK cell number recovery may be complete by this time after first treatment Febrile illness/infection within previous two weeks. Rationale, immune biomarkers will reflect previous febrile illness Current tobacco or tobacco use within 1 hour of start of SFIT. Rationale: forest oils may cause contact dermatitis and coughing Prior autoimmune disease, are on immune-modulating therapies (endocrine therapy allowed). Rationale, because of their poor prognosis rather than being in early stages of cancer Had surgery or invasive procedure in the past two months. Rationale, because of their poor prognosis rather than being in early stages of cancer Inability to complete study requisites
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amy M Ross, Ph.D.
Organizational Affiliation
OHSU Knight Cancer Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
OHSU Knight Cancer Institute
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Humidified Forest Oils for Immune System Recovery in Stage I-III Breast or Prostate Cancer

We'll reach out to this number within 24 hrs